Although the CROWN trial did not provide the specific treatment sequence after first-line treatment failure, we included possible clinical practices (BSC, surgery, chemotherapy and radiation) during the continuing treatment phase and calculated the subsequent treatment cost for patients with ALK+ NSCLC based on the previous study conducted by Deirdre. This evidence concerns the gene ALK and non-small cell lung carcinoma.